$45.29▲ 0.34 (0.76%)
Real-time prices · US MarketsClean balance sheet with low leverage (0.4× debt-to-equity).
Quality
7.7
Health
9.1
Growth
8.8
Valuation
8.6
Sentiment
8.5
Analyst Target
$77.10
▲ +70.2% from current
Price Chart
Latest News
- Global ECG Patch and Holter Monitor Market Size/Share Worth USD 3.92 Billion by 2035 at a 9.2% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)
- This Undervalued Medical-Devices Stock Is Poised for a Rebound
- Penumbra wins CE mark for Thunderbolt clot removal tech
Fundamentals
Trailing P/E
18.9×
price-to-earnings
Forward P/E
12.2×
next 12 months est.
Market Cap
$67.3B
market capitalization
Div Yield
—
dividend yield
Profit Margin
17.3%
net profit margin
Gross Margin
68.9%
revenue minus COGS
ROE
14.7%
return on equity
Beta
0.56
vs S&P 500
52-Week Range
$44 — $110
annual min — max
EPS — Estimate vs Actual
Frequently Asked Questions
What do analysts say about Boston Scientific Corporation right now?
Boston Scientific Corporation's Q·Score is 8.5/10 (Very Bullish), reflecting its current fundamentals, analyst data, and valuation metrics. Clean balance sheet with low leverage (0.4× debt-to-equity). This is an informational data summary only and does not constitute financial advice. Always do your own research before making any investment decision.
What is the analyst price target for BSX?
The consensus price target for BSX is $77.10, based on ratings from 30 Wall Street analysts. This is 70.2% above the current price of $45.29. Price targets are forward-looking estimates and not guarantees of future performance.
Is BSX overvalued or undervalued?
Boston Scientific Corporation (BSX) scores favorably on valuation metrics relative to sector peers and analyst targets. Its forward P/E ratio stands at 12.2×. The consensus analyst price target of $77.10 is 70% above the current price.
When does Boston Scientific Corporation report its next earnings?
Boston Scientific Corporation's next earnings report is expected on approximately July 29, 2026.
What is Boston Scientific Corporation's profit margin?
Boston Scientific Corporation has a net profit margin of 17.3%, which is solid for most industries. Its gross margin stands at 68.9%, indicating a high-margin business model.
Is Boston Scientific Corporation's revenue growing?
Boston Scientific Corporation is reporting solid revenue growth of 11.6% year-over-year. Earnings are also growing at 100.0%, indicating improving profitability.
How much debt does Boston Scientific Corporation have?
Boston Scientific Corporation has a debt-to-equity ratio of 0.42×, reflecting a moderate debt level, which is manageable for most profitable companies. Its current ratio is 1.90×, indicating comfortable short-term liquidity.